VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Inclacumab was generally well tolerated in THRIVE-131
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
Reinforcing commitment to ethical and sustainable growth
Subscribe To Our Newsletter & Stay Updated
